Pharma BD Deal Intelligence

Novartis AG / PeptiDream Inc.

2024 · Licensing/Option · $2.9B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Novartis expanded its collaboration with PeptiDream, paying $180M upfront for access to its macrocyclic peptide discovery platform across multiple undisclosed indications.

Key facts

Announced Apr 30, 2024
Closed Apr 30, 2024
Deal value $2.9B
Deal type Licensing/Option
Therapeutic area Oncology
Indications Multiple undisclosed, Diagnostics (PET imaging)
Key assets Macrocyclic peptides (platform)
Mechanism Macrocyclic peptide

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals